For the AML patients with CR/PR response status, the abundance of TUBA1B+CD8+ T−C1 and DYNLL1+Mac-C1 was higher, while the abundance of TUBA1A+Mac-C3 was lower (Figure 7A). This evidence concerns the gene MACC1 and acute myeloid leukemia.